Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hey Aber, not a bad shout. That’s my figure in my mind. £2bn mcap perhaps once chk1 in anogenial fast track orphan status and maybe other indications. Then our treasured tyk2/jak1 once in clinical trials and maybe end of p1 trials and then a good readout of data. Then a buyout.
Intraday is only there to test our patience. We have been here from 0.3p so keep holding on to those nuggets.
All my opinion of course.
Love peace and harmony.
Is hard word to spell at this hour. However, lest not forget that Sir Tim without stating as much,said that you’d practically need to eat the stuff to get some sort of result in the MTD.
The consolidation does whiff of a possible off shoot or amalgamation to a larger pharmacy imo.
Never mind the January blues, or February, there has been no news released which is negative.
Keep tight hold of those shares, ignore intraday , look long term.
Love peace and harmony
Looking a lot like Sierra at the moment. We mentioned share consolidation at a AGM prior and it was dismissed by the board as not being apt, however we are now going to progress with it.
Bought into Sierra back when some lady bought a shed load of shares, and they had the warning from the American market that unless they had a share value of $1 dollar or more , then they would be unlisted. Now showing as a 100% increase on the investment.
Now Sierra are loaded with tutes. Gilead one of them. Albeit eyes on momo and let’s hope they succeed. It was a total curve ball from them to buy a compound back for $3m dollars or thereabouts whilst, as we say, gangbustering chk1.
The MTD has been mentioned by Sir Tim as being a good problem to have. Then suddenly we are going for a capsule formulation, rather than an oral dose. We have proved we are better than current antiviral treatments for Covid.
We have, as mentioned many times on here, gleaned the material input of a few millionaires. Perhaps they are not as impatient as lower spectrum investors, like myself, ha!
Then we get shorted to death and finally Parker comes good, buying in at three pence and a bit. Uber confidence.
Apart from my own twitchy bum and impateince ,there seems to be no need to sell up . At least not until we have a licensing deal for tyk2 in autoimmune and cancer. June we have been told at the latest.
Got my pedallo ready.
Love peace and harmony.
We’ve been here a while now. Personally only since 2016. Patience can send you mad if you let it. Look where we are now though. Chk1 potentially with other molecules in p2 trials ( when we bought in this was preclinical), and now two tyk2 molecules almost ready for clinical trials.
Sareum business model is to on licence in preclinical and / or early p1. This is sure to happen, so yes, sometime in 2022. People scoffed Sareum back then, claiming jam next year and nowt now.
Fortunately there are just over 1.6m of these shares stuck in my sipp, at not a great cost, round about 9k, and a few hundred thousand in an isa. I took some jam from the isa and am prepared to get to the finish line now. So holding tight and awaiting a glorious outcome. Fingers crossed , retirement looms at 57 :)
Hope you manage to stay the course warthog4.
Love peace and harmony.
Covid news, and trials not to start till mid 22, it feels similar to an earlier period in Sareums history, when we were informed of no news coming forthwith and we saw the share price drop, all the way down to the low thirty’s. Shorting it was easy back then as the price was already low as was the volume. Maybe this time it will be different as the whole set up of Sareum has changed, for the better, and any news of a positive RNS prior to next year would send this share sky high.
My shares are tightly gripped in my hand and it’s glued to the A45.
Love peace and harmony.
Looks like not only a way of biomarking an individual to determine if they are likely to benefit from Tyk2, but also a way to transport and manufacture a crystalline form and determine it’s quality.
A gut feeling says to have that patent is better than not having it.
As per Dr.Parker, we are heading to clinic.
It’s just a waiting game.
Love peace and harmony.
We know jak2 causes bone brittleness over time. That’s why we invested early doors as ours will not inflict that.
What we don’t know is if our tyk2 is going AGILE. Interesting tweet from Stephen regarding we are going to clinic, as he mentioned it alongside a cancer therapy retweet or whatever they are.
As always, keep the faith.
The thing is; AGILE adds much value short term, and alongside our cancer molecule on a longer term, perhaps, we can be heading to the moon.
Got to admit, news on this front is teasing my patience.
Love peace and harmony.
The way it appears is that we have a roadmap for our autoimmune and cancer tyk2 , however, regarding COVID-19, in spite of downregulating the ARDS in appropriate trials, we have no update on potential p1/p2 trials.
Love peace and harmony.
Hey Utah , and Warthog, it’s a big difference in scenario since the heady 0.85p days. Those days when you informed us you couldn’t sell etc. It feels , now, like you are genuine investors. Not that it matters. We get to £3 a share, and you will be invited to the directors box at a SAFC game v Sheffield Wednesday.
Seriously though, regarding Covid , TYk2 and Sareum I expect some news soon.
Love peace and harmony.
Raised earlier regarding the incoming license deals and what to do with the upfront payments.
When WHO are talking about Tyk2, we find ourselves with two of those beautiful golden nuggets, or three. Autoimmune cancer and covid.
What an opportunity my fellow brethren to build a portfolio.
Love peace and harmony.